NABARSI

New AntiBacterials with Inhibitory activity on Aminoacyl-tRNA Synthetases

 Coordinatore ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM 

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Dr.
Nome: John
Cognome: Hays
Email: send email
Telefono: +3101070 32177
Fax: +3101070 36875

 Nazionalità Coordinatore Netherlands [NL]
 Totale costo 5˙389˙151 €
 EC contributo 4˙102˙157 €
 Programma FP7-HEALTH
Specific Programme "Cooperation": Health
 Code Call FP7-HEALTH-2013-INNOVATION-2
 Funding Scheme CP-FP
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-06-01   -   2016-05-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM

 Organization address address: 's Gravendijkwal 230
city: ROTTERDAM
postcode: 3015CE

contact info
Titolo: Dr.
Nome: John
Cognome: Hays
Email: send email
Telefono: +3101070 32177
Fax: +3101070 36875

NL (ROTTERDAM) coordinator 577˙819.20
2    OMNIA MOLECULAR S.L.

 Organization address address: Calle JOSEP SAMITIER - PARC CIENTIFIC DE BARCELONA 1-5
city: BARCELONA
postcode: 8028

contact info
Titolo: Dr.
Nome: Lluis
Cognome: Ribas De Pouplana
Email: send email
Telefono: +34 934034868
Fax: +34 934034970

ES (BARCELONA) participant 1˙042˙132.30
3    InhibOx Limited

 Organization address address: CORNHILL 24
city: LONDON
postcode: EC3V 3ND

contact info
Titolo: Dr.
Nome: Paul
Cognome: Finn
Email: send email
Telefono: +44 1865 261468

UK (LONDON) participant 1˙013˙501.00
4    LATVIJAS ORGANISKAS SINTEZES INSTITUTS

 Organization address address: AIZKRAUKLES 21
city: RIGA
postcode: 1006

contact info
Titolo: Ms.
Nome: Dace
Cognome: Karkle
Email: send email
Telefono: +371 67014803

LV (RIGA) participant 848˙025.00
5    UNIVERSITY OF LEEDS

 Organization address address: WOODHOUSE LANE
city: LEEDS
postcode: LS2 9JT

contact info
Titolo: Mr.
Nome: Martin
Cognome: Hamilton
Email: send email
Telefono: +44 113 3434090

UK (LEEDS) participant 620˙680.00

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

human    aars    uk    discovery    leeds    lios    nces    erasmusmc    nabarsi    resistance    compounds    resistant    chemical    mdr    drug    omnia    co    sme    inhibox    antibacterial   

 Obiettivo del progetto (Objective)

'The NABARSI consortium will develop a cutting-edge drug discovery project to increase the antibacterial pipeline. The main goal of NABARSI is to find new chemical entities (NCEs) with antibacterial efficacy in animal models of multi-drug resistant (MDR) bacterial infection and to exploit the results through obtaining a co-development with industry. The NABARSI consortium consists of 5 partners: Omnia Molecular (Omnia, SME; Spain). InhibOx (SME, UK). Latvian Institute of Organic Synthesis (LIOS, Latvia), Leeds University (Leeds, UK) and Erasmus Medical Centre (ErasmusMC, The Netherlands - Coordinator). Antibacterial activity will be achieved through inhibition of essential aminoacyl-tRNA synthetases (aaRS). Individual aaRS are highly conserved across bacteria, enabling the discovery of broad-spectrum antibacterials. To reduce the likelihood of resistance, NABARSI will look for NCEs with inhibitory activity against multiple aaRS enzymes. InhibOx and LIOS will design NCEs by rational and fragment based drug discovery methods followed by synthetic structure optimization. To increase chemical diversity, virtual screening of large (>100 M) compound libraries available at InhibOx will be performed. Limitations of previous aaRS inhibitors will be overcome by novel approaches such as the In Omnia assay: activity of the compounds on pathogenic aaRS enzyme is measured inside a human cell, allowing rejection of compounds acting through human aaRS and identifying compounds that cross biological membranes. The expertise of Leeds in mode of action studies will be used at an early stage. Activity of the NCEs on clinical isolates of MDR strains available at ErasmusMC will be assessed. Resistance appearance frequency and mechanisms will also be assessed early by selection and characterization of resistant mutants by ErasmusMC and Leeds. A co-development agreement with pharmaceutical companies will be intensively sought with the aim of exploiting the NCEs upon finalisation of NABARSI.'

Altri progetti dello stesso programma (FP7-HEALTH)

PEACHI (2013)

Prevention of hepatitis C virus (HCV) and HIV-1 co-infections through induction of potent T cell responses using prime-boost viral vector vaccine regimens

Read More  

EUROVISIONNET (2008)

Visual Impairment and Degeneration: A Road-map for Vision Research within Europe

Read More  

IACOBUS (2013)

"Diagnosis and Monitoring of Inflammatory and Arthritic diseases using a COmbined approach Based on Ultrasound, optoacoustic and hyperSpectral imaging"

Read More